Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGD020 · 1 trial · 3 indications
Observation of side effects determines the highest safe dose for further study
Observation of side effects determines the highest safe dose for further study
Observation of side effects determines the highest safe dose for further study
| Arm | Type | Description |
|---|---|---|
| Part 1A: Dose level 1 | EXPERIMENTAL | Single dose MGD020 |
| Part 1A: Dose level 2 | EXPERIMENTAL | Single dose MGD020 |
| Part 1A: Dose level 3 | EXPERIMENTAL | Single dose MGD020 |
| Part 1A: Dose level 4 | EXPERIMENTAL | Single dose MGD020 |
| Part 1A: Dose level 5 | EXPERIMENTAL | Single dose MGD020 |
| Part 1A: Dose level 6 | EXPERIMENTAL | Single dose MGD020 |
| Part 1B: MTD/MAD -1 MGD020 and MGD014 | EXPERIMENTAL | Single dose MGD020 and MGD014 |
| Part 1B: MTD/MAD MGD020 and MGD014 | EXPERIMENTAL | Single dose MGD020 and MGD014 |
| Part 2: MGD020 and MGD014 | EXPERIMENTAL | Multiple doses of MGD020 and MGD014 |
| Name | Type | Description |
|---|---|---|
| MGD020 | BIOLOGICAL | MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope. |
| MGD014 | BIOLOGICAL | MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope. |
Inclusion Criteria: * Aged ≥ 18 years and ≤ 70 years of age and able to provide informed consent * HIV-1 infection documented by rapid HIV test or HIV enzyme or chemiluminescence immunoassay and confirmed by a different second test. * Plasma HIV-1 RNA viral load * \< 50 copies/mL at 2 time point...
MGD020 is an investigational monoclonal antibody being developed for the treatment of Human Immunodeficiency Virus I Infection (HIV-1). It is currently in Phase 1 clinical development and has been studied in patients with HIV-1 who are on antiretroviral therapy.
MGD020 is a monoclonal antibody designed to target HIV-1. It is being studied for its potential to treat Human Immunodeficiency Virus I Infection, and it is being evaluated alone or in combination with another investigational antibody, MGD014, in clinical trials.
MGD020 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol MGNX. The company is conducting clinical research on this investigational monoclonal antibody for the treatment of HIV-1 infection.
MGD020 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 study of MGD020 has been completed, and the drug remains in early-stage clinical evaluation for HIV-1 infection.
MGD020 has been studied in one clinical trial, identified as NCT05261191, titled 'A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy.' This Phase 1 trial enrolled 17 participants in the United States and has been completed.
No, MGD020 and MGD014 are different investigational monoclonal antibodies. They are being studied together in a clinical trial for HIV-1 infection, where MGD020 is evaluated alone or in combination with MGD014. Both are being developed by MacroGenics, Inc.